Phase I trial of Exisulind (Aptosyn™) and CPT-11 in patients with colorectal cancer and other solid tumors.

被引：0
|
作者：
Marshall, JL [1 ]
Park, S [1 ]
Al-Sayed, A [1 ]
Fox, E [1 ]
Rizvi, N [1 ]
机构：
[1] Vincent T Lombardi Canc Res Ctr, Washington, DC USA
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
295
引用
收藏
页码：3713S / 3713S
页数：1
相关论文
共 50 条
  • [21] Phase I trial of escalating doses of irinotecan (CPT-11) in combination with UFT/folinic acid (FA) in patients with advanced colorectal cancer (CRC).
    Gravalos, C
    Garcia-Alfonso, P
    Castellanos, D
    Martin, B
    Perez-Manga, G
    Cortes-Funes, H
    Gonzalez-Lama, J
    Paz-Ares, L
    ANNALS OF ONCOLOGY, 2000, 11 : 46 - 46
  • [22] A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
    Manabu Shiozawa
    Nobuhiro Sugano
    Kazuhito Tsuchida
    Soichiro Morinaga
    Makoto Akaike
    Yukio Sugimasa
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 365 - 370
  • [23] A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
    Shiozawa, Manabu
    Sugano, Nobuhiro
    Tsuchida, Kazuhito
    Morinaga, Soichiro
    Akaike, Makoto
    Sugimasa, Yukio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (03) : 365 - 370
  • [24] Two schedules of CPT-11 in patients with advanced colorectal cancer (ACC)
    Reutova, E
    Gorbounova, V
    Orel, N
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 425 - 425
  • [25] Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors.
    Gold, PJ
    Refice, S
    West, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 164S - 164S
  • [26] A phase I trial of sarcosinamide nitrosourea in adult patients with solid tumors.
    Puchalski, TA
    Eder, JP
    Ryan, DP
    Clark, JW
    Castellana, W
    Garcia-Carbonero, R
    Kufe, DW
    Supko, JG
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3709S - 3709S
  • [27] A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
    Rothenberg, ML
    Cox, JV
    DeVore, RF
    Hainworth, JD
    Pazdur, R
    Rivkin, SE
    Macdonald, JS
    Geyer, CE
    Sandbach, J
    Wolf, SL
    Mohrland, JS
    Elfring, GL
    Miller, LL
    Von Hoff, DD
    CANCER, 1999, 85 (04) : 786 - 795
  • [28] Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
    Chinnaiyan, Prakash
    Chowdhary, Sajeel
    Potthast, Lisa
    Prabhu, Antony
    Tsai, Ya-Yu
    Sarcar, Bhaswati
    Kahali, Soumen
    Brem, Steven
    Yu, H. Michael
    Rojiani, Amyn
    Murtagh, Ryan
    Pan, Edward
    NEURO-ONCOLOGY, 2012, 14 (01) : 93 - 100
  • [29] A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
    N E Schoemaker
    I E L M Kuppens
    V Moiseyenko
    B Glimelius
    M Kjaer
    H Starkhammer
    D J Richel
    R Smaaland
    K Bertelsen
    J P Poulsen
    E Voznyi
    J Norum
    D Fennelly
    K M Tveit
    A Garin
    G Gruia
    A Mourier
    D Sibaud
    P Lefebvre
    J H Beijnen
    J H M Schellens
    W W ten Bokkel Huinink
    British Journal of Cancer, 2004, 91 : 1434 - 1441
  • [30] A phase I study of bi-weekly administration of 24-hr gemcitabine (GEM) followed by 24-hr irinotecan (CPT-11) in patients with solid tumors.
    Saif, MW
    Sellers, S
    Li, M
    Wang, W
    Cusimano, L
    Wang, H
    Zhang, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 159S - 159S
12345